

Allegato B

Decreto Rettore Università di Roma “La Sapienza” n 169/2018 del 18/01/2018

COSIMO DURANTE

Curriculum Vitae

Place: Roma

Date: 14/02/2018

Part I – General Information

Full Name	Cosimo Durante
Spoken Languages	Italian, English, French

Part II – Education and Fellowships

IIA – Education

Type	Dates	Institution	Notes
University graduation	1994 - 2000	University of Rome Sapienza	Degree in Medicine and Surgery
Post-graduate studies	2000 - 2005	University of Rome Sapienza	Board in Endocrinology and Metabolism
PhD	2005 - 2008	University of Rome Sapienza	Degree in Endocrinology and Molecular Medicine

IIA – Fellowships

Type	Dates	Institution	Responsible
Clinical-Research Fellowship	03/11/2003 - 31/10/2004	Department of Nuclear Medicine and Endocrine	Martin Schlumberger, MD

		Oncology, Institut Gustave Roussy and Université Paris Saclay, 114 rue Edouard Vaillant, 94800, Villejuif, France	
--	--	---	--

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
01/11/2008	Present	University of Rome Sapienza, Department of Internal Medicine and Medical Specialties	Assistant Professor of Internal Medicine
01/11/2011	31/10/2016	University of Rome Sapienza, Viterbo venue	Vice President of the Degree Programme “Psychiatric Rehabilitation Techniques” (code: 15986; degree: bachelors), Medicine and Dentistry Faculty
01/11/2009	31/10/2016	University of Rome Sapienza, Viterbo venue	Coordinator the Integrated Course “Psychiatric Rehabilitation in Internal Medicine” (code: 1036272), Degree Programme “Psychiatric Rehabilitation Techniques” (code: 15986; degree: bachelors), Medicine and Dentistry Faculty
01/11/2012	31/10/2016	University of Rome Sapienza, Viterbo venue	Coordinator the Integrated Course “Clinical Nursing in Medical Area” (code: 1035917), Degree Programme “Obstetrics” (code: 15963; degree: bachelors), Medicine and Dentistry Faculty
01/11/2015	31/10/2017	University of Rome Sapienza	Member of the Sapienza Research Committee
25/01/2016	Present	University of Rome Sapienza	Member of the Medical Education Committee Inter Faculty (CMEI)

06/04/2017	06/04/2023	Italian Ministry of Education, Universities and Research (MIUR)	Awarded the National Scientific Qualification for Associate Professor for the SC 06/B1, SSD MED/09, Call 2016 (D.D. 1532/2016)
------------	------------	---	--

IIIB – Clinical Appointments

Start	End	Institution	Position
17/10/2011	Present	Policlinico Umberto I of Rome, Unit of Internal Medicine and Metabolic Diseases	Medical Doctor in Internal Medicine
14/12/2016	Present	Policlinico Umberto I of Rome, Unit of Internal Medicine and Metabolic Diseases	Responsible of the Unit (UOS) on the Management of the Advanced Thyroid Tumors

IIIC – Other Appointments: Institutional Committee Activities

Start	End	Institution	Activity
08/03/2011	Present	Italian Ministry of Education, Universities and Research (MIUR)	Member of Expert Peer Reviewers for Italian Scientific Evaluation (REPRISE)
17/10/2014	12/08/2015	Italian Society of Endocrinology (SIE)	Member of the SIE Task Force for the preparation of the document: "Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology"
26/01/2015	Present	Italian Association Of Medical Oncology (AIOM)	Scientific secretary of the "AIOM Thyroid Tumors Guidelines", Edition 2016, 2017
31/05/2016	08/08/2017	European Thyroid Association (ETA)	Member of the ETA Task Force for the preparation of the document: "European Thyroid

			Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS", Edition 2017
06/05/2016	Present	Italian Thyroid Association (AIT), Medical Endocrinology Association (AME), Italian Society of Endocrinology (SIE), Italian Association of Nuclear Medicine and Molecular Imaging (AIMN), Italian Society of Unified Endocrine Surgery (SIUEC), Italian Society of Anatomic Pathology and Diagnostic Cytology (SIAPEC)	Member of the AIT, AME, SIE, AIMN, SIUEC, SIAPEC Task Force for the preparation of the document: "Italian Consensus on Diagnosis and Treatment of Differentiated Thyroid Cancer: Joint Statements of Six Italian Societies"
29/01/2018	Present	International Thyroid Oncology Group (ITOG)	Member of the ITOG Task Force for establishing an International Advanced Thyroid Cancer Registry

Part IV – Teaching experience

IVA – Single Cycle, Bachelors Degree

Dates	Institution/Faculty	Degree/Programme/Course
01/11/2009 - 31/10/2016	University of Rome Sapienza, Viterbo venue/Medicine and Dentistry	Bachelors/Psychiatric Rehabilitation Techniques (code: 15986)/Internal Medicine
01/11/2012 - 31/10/2016	University of Rome Sapienza, Viterbo venue/Medicine and Dentistry	Bachelors/Obstetrics (code: 15963)/Internal Medicine
01/11/2013 - 31/10/2016	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery A (code: 26647)/Clinical scientific methods VI

01/11/2014 - present	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery A (code: 26647)/ Internal Medicine and General Surgery I
01/11/2016 - present	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery F (code: 15342)/ Internal Medicine and General Surgery III
01/11/2017 - present	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery A (code: 26647)/ Internal Medicine and General Surgery III

IVB – Specialization course

Dates	Institution/Faculty	Programme
01/11/2011 - present	University of Rome Sapienza/Pharmacy and Medicine	Internal Medicine (code: 28270)

IVC – PhD Degree

Dates	Institution	Programme
01/11/2011 - present	University of Rome Sapienza	Biotechnology in Clinical Medicine (code: 11124)

IVD – Master Degree

Dates	Institution	Programme/Course
01/11/2011 - present	University of Rome Sapienza	Sonography in Internal Medicine (code: 15299)/Neck ultrasound

Part V - Society memberships, Awards and Honors

Dates	Title
2010 - present	Member of the American Thyroid Association (ATA)
2012 - present	Member of the European Thyroid Association (ETA)
2012 - present	Member of the “Società Italiana di Medicina Interna” (SIMI)
2013 - present	Member of the “Collegio dei Docenti Universitari MED/09 di Medicina Interna”

	(COLMED)
2013 - present	Member of the “Società Italiana di Endocrinologia” (SIE)
2015 - present	Member of the International Thyroid Oncology Group (ITOG)
2017 - present	Member of the European Society of Endocrinology (ESE)
2017 - present	Member of the European Organization for Research and Treatment of Cancer (EORTC), Endocrine Group

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

VIA – Competitive National or International Research Funding

Dates	Title	Program	Grant value
01/12/2010 – 01/03/2014	Ex vivo evaluation of targeted therapies against the tyrosine kinase receptor MET: Identification of genetic and biological determinants for prediction of treatment efficacy (code: RBFR082XL7_003)	2008 Fund for Investment in Basic Research (FIRB), by Ministry of Education, Universities and Research (MIUR), “Futuro in Ricerca” Program	314,000 euro
31/12/2016 – present	Thyroid cancer and cytologically indeterminate thyroid nodules: new diagnostic and therapeutic strategies for a more precise patient tailored medicine and a more sustainable management of a disease with a great social impact (code: 2015HPMLFY_013)	2015 Research Projects of National Interest (PRIN), by Ministry of Education, Universities and Research (MIUR)	47,500 euro

VIB – Other Competitive Funding

Dates	Title	Program	Grant value
30/01/2011 – 30/04/2012	RNA expression profile of Notch and related genes in sporadic and hereditary medullary	2010 University of Rome Sapienza Grant	31,500 euro

	thyroid cancer according to RET mutational status (code: C26A104493)		
30/01/2012 – 30/04/2013	Identification of new genes involved in the development of wild-type RET familial medullary thyroid carcinoma (code: C26A11WKT7)	2011 University of Rome Sapienza Grant	36,818 euro
30/11/2012 – 29/05/2014	Thyroid cancer stem cells: looking for new targets (code: C26A12HN79)	2012 University of Rome Sapienza Grant	12,000 euro
09/12/2013 – 24/03/2015	Diagnostic and prognostic role of microRNAs in Papillary Thyroid Carcinoma (code: C26A13C8C7)	2013 University of Rome Sapienza Grant	11,000 euro
21/11/2014 – 05/05/2016	Beyond RET: identification of new susceptibility genes for medullary thyroid cancer using a next generation sequencing-based approach (code: C26A14FE4A)	2014 University of Rome Sapienza Grant	13,000 euro
30/11/2015 – 09/06/2017	Beyond RET: identification of new susceptibility genes for medullary thyroid cancer using a next generation sequencing-based approach (code: C26A14FE4A)	2015 University of Rome Sapienza Grant	8,000 euro

Part VII – Research Activities

VIIA – Research Interests

Keywords	Brief Description
Thyroid nodule	– Defining the thyroid nodule risk of malignancy according to sonographic pattern and molecular profile – Defining risk-adapted management strategies for thyroid nodule screening, treatment and long-term follow-up
Thyroid cancer	– Defining new thyroid cancer staging systems to predict the post-

	operative risk of persistent/recurrent disease – Identifying new risk-adapted management strategies to tailoring the initial treatment and the follow-up protocol to the risk of persistent/recurrent disease
Next Generation Sequencing	– Identifying new molecular markers to be used as diagnostic, prognostic and predictive factors for the management of thyroid nodules and thyroid cancer – Identifying new thyroid cancer driver alterations to allow treatment with matched target therapies
Big data	– Creating and assembling database networks within a single country or in the context of a multinational collaboration for studying and improving patient care through clinical epidemiologic research (currently established database and collaborations: Italian Thyroid Cancer Observatory [ITCO], International Thyroid Oncology Group [ITOG] Advanced Thyroid Cancer Registry)

VIIB – Coordination of National or International Research Projects

Dates	Setting	Title
01/11/2003 – 30/04/2006	International	Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
01/01/2006 – present	National	The natural history of benign thyroid nodules
01/10/2006 – 30/04/2007	National	BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism
01/12/2007 – 31/01/2009	International	Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
08/01/2010 – 21/07/2010	National	Identification and Optimal Postsurgical Follow-Up of Patients with Very Low-Risk Papillary Thyroid Microcarcinomas
28/05/2010 – 08/06/2011	National	BRAF (V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas
14/01/2011 – 12/08/2011	National	Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors
25/11/2011 – 07/06/2012	National	Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement?

14/01/2012 – 27/12/2012	National	Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance
21/06/2013 – 09/05/2014	International	Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours
06/09/2013 – 14/09/2015	National	Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers
11/01/2014 – 21/05/2014	National	Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies
10/01/2015 – 14/12/2015	National	Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients
10/01/2015 – 08/07/2016	National	RET mutation and increased angiogenesis in medullary thyroid carcinomas
16/01/2015 – 14/08/2015	National	BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study
14/07/2015 – 17/05/2017	National	Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer.
27/12/2016 – 14/09/2017	National	Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume
09/02/2017 – 30/11/2017	National	8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2)

VIIC – Participation to International Clinical Trials

Dates	Position	Title
2004 – 2005	Sub-Investigator	A Phase 2, Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer who are not Candidate for Radioactive Iodine Therapy (ClinicalTrials.gov: NCT00121628)
2006 – 2016	Sub-Investigator (2006-2015) – Principal Investigator (from 01/09/ 2015)	An International, Phase II/III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (Zactima) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer (ClinicalTrials.gov: NCT0041076. Study ID Number: D4200C00058)
2009 – 2014	Sub-Investigator	A Phase II, Multicenter, Open Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in

		Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (ClinicalTrials.gov: NCT00784303. Study ID Number: E7080-G000-201)
2009 – 2014	Sub-Investigator	An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer (ClinicalTrials.gov: NCT00704730. Study ID Number: XL184-301)
2010 – present	Sub-Investigator (2010-2015) – Principal Investigator (from 01/09/ 2015)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer (ClinicalTrials.gov: NCT01321554. Study ID Number: E7080-G000-303)
2011 – 2014	Sub-Investigator	A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib (ClinicalTrials.gov: NCT01298323. Study ID Number: D4200C00088)
2012 – 2015	Sub-Investigator	An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease (ClinicalTrials.gov: NCT01496313. Study ID Number: D4200C00097)
2013 – 2017	Sub-Investigator (2013-2015) – Principal Investigator (from 01/09/2015)	A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy (ClinicalTrials.gov: NCT01876784. Study ID Number: D4203C00011)
2013 – present	Sub-Investigator (2013-2015) –	A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of

	Principal Investigator (from 01/09/2015)	Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer (ClinicalTrials.gov: NCT01843062. Study ID Number: D1532C00065)
2017 – present	Principal-Investigator	A Randomized, Double-Blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients (ClinicalTrials.gov: NCT01896479. Study ID Number: XL184-401)

Part VIII– Editorial and Review Activities

VIII A – Editor/Service on Editorial Board(s)

Start	End	Journal (Impact Factor Ranking)	Position
01/01/2014	31/12/2016	The Journal of Endocrinological Investigation (InCites Journal Impact Factor Quartile: Q3)	Member of the Editorial Board
01/01/2014	31/12/2017	The Journal of Clinical Endocrinology & Metabolism (InCites Journal Impact Factor Quartile: Q1)	Member of the Editorial Board

VIII B – Editor of Textbook(s)

Dates	Title	Editor(s)	Publisher
2016	Thyroid Cancer. A Case-Based Approach (DOI: 10.1007/978-3-319-22401-5. Print ISBN: 978-3-319-22400-8. Online ISBN: 978-3-319-22401-5)	David S. Cooper, Cosimo Durante	Springer International Publishing

VIII C – Journal Reviewer

Journal	InCites JIF Quartile	Number - total (last 5-yrs)
The Journal of Clinical Endocrinology	Q1	19 (19)

& Metabolism		
Thyroid	Q1	14 (13)
Endocrine-Related Cancer	Q1	3 (2)
Oncotarget	Q1	2 (2)
British Medical Journal	Q1	1 (1)
Human Pathology	Q1	1 (0)
Oncologist	Q1	1 (1)
QJM-An International Journal of Medicine	Q1	1 (1)
Endocrine	Q2	9 (6)
Clinical Endocrinology	Q2	1 (0)
Molecular and Cellular Endocrinology	Q2	1 (1)
Journal of Endocrinological Investigation	Q3	13 (9)
International Journal of Endocrinology	Q3	3 (3)
European Thyroid Journal	NA	2 (2)

JIF, Journal Impact Factor; Q, quartile; NA, not applicable

Part IX- Conferences and Symposia

IXA – Invited Speaker at International Conferences promoted by National or International Scientific Societies

Dates	Conference/ Site	Title
10/07/2013 – 14/07/2013	2nd World Congress on Thyroid Cancer (WCTC), Toronto, Canada.	Detection of recurrent disease in differentiated thyroid cancer: Estimating the risk for disease recurrence
09/10/2013 – 11/10/2013	33rd Annual Meeting of the British Association of Endocrine & Thyroid Surgeons (BAETS), Roma, Italia	US and US-guided operative procedures for endocrine and thyroid surgeons: Endocrinological perspectives
06/09/2014 – 10/09/2014	38th Annual Meeting of the European Thyroid Association (ETA), Santiago de Compostela,	Outcome of metastatic thyroid cancer

	Spain	
18/10/2015 – 23/10/2015	15th International Thyroid Congress, Lake Buena Vista, Florida, USA	Technical and clinical pitfalls in thyroglobulin assays
17/03/2016	Journée Annuelle du Groupe de Recherche sur la Thyroïde, Paris, France	Histoire naturelle des nodules et goitres multi-nodulaires
03/09/2016 – 06/09/2016	39th Annual Meeting of the European Thyroid Association (ETA), Copenhagen, Denmark	Should we care about benign thyroid nodules. Follow-up of fine needle biopsy
10/09/2016	10ème Symposium sur le Cancer de la Thyroïde, Quebec City, Canada	Les cancers thyroïdiens à faible risque
29/09/2016	5ème Journée Thyroïde – Tumeurs Endocrines de l'Institut Universitaire de Cancérologie, Paris, France	Management of papillary thyroid carcinomas with incomplete or indeterminate responses to initial treatment
31/01/2017 – 01/02/2017	2nd Differentiated Thyroid Cancer Symposium, Riyadh, Kingdom of Saudi Arabia	1. Molecular testing in the evaluation of thyroid nodules 2. Non-surgical management of thyroid nodules 3. Role of ultrasound in the follow-up of thyroid cancer
13/05/2017	Belgian Thyroid Club, 50th Meeting, Meise, Belgium	Long-term follow-up of patients with benign thyroid nodules
26/05/2017 – 27/05/2017	Congrès Annuel de l'Association des Médecins Endocrinologues du Québec, Quebec City, Canada	Suivi à long terme de cancer différencié de la thyroïde: Par qui et comment?
27/07/2017 – 30/07/2017	3rd World Congress on Thyroid Cancer (WCTC), Boston, Massachusetts, USA	Evaluation and management of recurrent thyroid cancer
09/09/2017 – 12/09/2017	40th Annual Meeting of the European Thyroid Association (ETA), Belgrade, Serbia	Cervical lymph nodes mapping: where to search and criteria for recurrence
24/11/2017 – 25/11/2017	47 Jahrestagung der Sektion Schilddrüse der Deutschen Gesellschaft für Endokrinologie, 47th Annual Meeting of the Thyroid Section of the German Endocrine Society, Bremen,	Natural evolution of thyroid nodules

	Germany	
27/11/2017 – 28/11/2017	Fall Meeting of the European Organisation for Research and Treatment of Cancer (EORTC)/Endocrine Task Force, Porto, Portugal	Microcarcinoma: what to do?

IXB – Invited Speaker at National Conferences promoted by National Scientific Societies

Dates	Conference/ Site	Title
24/02/2011 – 26/02/2011	2° Meeting Interannuale CO.R.Te. (Conferenza Italiana per lo Studio e la Ricerca sulle Ulcere, Piaghe, Ferite e la Riparazione Tessutale), Bologna, Italia.	Cellule staminali della tiroide
18/03/2011 – 21/03/2011	X Congresso Nazionale Associazione Italiana di Medicina Nucleare (AIMN), Rimini, Italia	Nuovi approcci terapeutici nel carcinoma tiroideo radioiodioresistente
22/05/2012 – 23/05/2012	VI Congresso Nazionale della Sezione della Società Italiana di Medicina Interna (SIMI) Lazio Molise, Roma, Italia	Il nodulo tiroideo
25/09/2012	1° Congresso Nazionale Società Italiana di Chirurgia (SIC) – Associazione Chirurghi Ospedalieri Italiani (ACOI), Roma, Italia	Acquisizioni in tema di trattamento delle neoplasie tiroidee con inibitori delle tirosino chinasi
07/03/2013 – 09/03/2013	XXX Congresso Nazionale della Società Italiana di Endocrinochirurgia (SIEC), Torino, Italia	Carcinoma papillifero della tiroide: le recidive dopo l'intervento
07/11/2013 – 10/11/2013	12° Congresso Nazionale Associazione Medici Endocrinologi (AME) – Joint Meeting with American Association of Clinical Endocrinologists (AACE), Bari,	Follow-up del carcinoma tiroideo a rischio intermedio-alto

	Italia	
05/12/2013 – 07/12/2013	7° Congresso Associazione Italiana della Tiroide (AIT), Roma, Italia	Gestione clinica del carcinoma refrattario al radioiodio
04/04/2014 – 05/04/2014	VIII Congresso Nazionale della Sezione della Società Italiana di Medicina Interna (SIMI) Lazio Molise, Roma, Italia	Il carcinoma della tiroide: gestione clinica di una epidemia
10/04/2014 – 12/04/2014	31° Congresso Società Italiana di Endocrinologia (SIE) – Giornate Endocrinologiche Pisane, Pisa, Italia	Gestione del paziente con carcinoma tiroideo avanzato
06/11/2014 – 09/11/2014	13° Congresso Nazionale Associazione Medici Endocrinologi (AME), Roma, Italia.	1. Dosaggio della tireoglobulina: metodi e trabocchetti. Real practice 2. Il problema dei TKI nel carcinoma tiroideo. Real practice
27/11/2014 – 29/11/2014	8° Congresso Associazione Italiana della Tiroide (AIT), Milano, Italia	Approccio farmacogenetico alla terapia dei carcinomi tiroidei. Il Carcinoma scarsamente differenziato
27/05/2015 – 30/05/2015	38° Congresso Nazionale Società Italiana di Endocrinologia (SIE), Taormina, Messina, Italia	Nuovi inibitori farmacologici nel trattamento del carcinoma papillifero della tiroide avanzato/metastatico
05/11/2015 – 08/11/2015	14° Congresso Nazionale Associazione Medici Endocrinologi (AME) – Joint Meeting with American Association of Clinical Endocrinologists (AACE), Rimini, Italia	La PET in oncologia tiroidea. Real clinical practice
03/12/2015 – 05/12/2015	9° Congresso Associazione Italiana della Tiroide (AIT), Udine, Italia	Un anno di tireologia. Studi clinici
19/05/2016 – 20/05/2016	1° Convegno Incontri Italiani di Endocrinologia e Metabolismo Convegno nazionale, Società Italiana di Endocrinologia (SIE), Pisa, Italia	Noduli tiroidei asintomatici, benigni: come seguirli?
11/11/2016 – 13/11/2016	15° Congresso Nazionale Associazione Medici	1. Trattamento del carcinoma tiroideo avanzato resistente al radioiodio

	Endocrinologi (AME) – Joint Meeting with American Association of Clinical Endocrinologists (AACE), Roma, Italia	2. Il microcarcinoma tiroideo. Trattamento o sorveglianza: quali sono le evidenze?
17/11/2016 – 19/11/2016	3° Congresso Nazionale Club Società Italiana di Endocrinologia (SIE) – Endocrinologia Oncologica, Torino, Italia	Ablazione tiroidea con Iodio 131: a chi, quando e come?
15/12/2016 – 17/12/2016	10° Congresso Associazione Italiana della Tiroide (AIT), Udine, Italia	La gestione del carcinoma differenziato della tiroide alla luce delle nuove linee guida: Diagnostica pre-intervento
02/03/2017 – 05/03/2017	XIII Congresso Nazionale Associazione Italiana di Medicina Nucleare (AIMN), Rimini, Italia	Classificazione della risposta al trattamento, stratificazione ongoing del rischio e gestione del paziente con risposta eccellente al trattamento
21/06/2017 – 24/06/2017	39° Congresso Nazionale Società Italiana di Endocrinologia (SIE), Roma, Italia	Nuovi paradigmi nella classificazione e gestione dei noduli tiroidei. Definizione di benignità: ruolo dell'ecografia e della citologia
09/11/2017 – 12/11/2017	16° Congresso Nazionale Associazione Medici Endocrinologi (AME) – Joint Meeting with American Association of Clinical Endocrinologists (AACE), Roma, It	Carcinoma avanzato della tiroide iodio-refrattario: Gestione degli effetti collaterali
30/11/2017 – 02/12/2017	11° Congresso Associazione Italiana della Tiroide (AIT), Torino, Italia	Applicazione clinica dei TKI
26/01/2018 – 27/01/2018	2° Associazione Medici Endocrinologi (AME) UpDate in Endocrinologia Oncologica, Udine, Italia	Carcinoma tiroideo differenziato radioiodio refrattario. La terapia medica: inibitori di TK

Part X- Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
--------------	--------	-----------	-------	-----

Papers [international]	86	PubMed, Scopus, Web of Science	2002	Present
Papers [national]	4	PubMed, Scopus	2006	Present
Books [editor]	1	Scopus	2014	Present
Book chapters [international]	5	Scopus, Google Scholar	2013	Present
Book chapters [national]	6	Google Scholar	2007	Present

Total Impact factor*	424,5 (InCites Journal Impact Factor)
Average Impact Factor per Product*	4,9 (InCites Journal Impact Factor)
Total Citations	2283 (Scopus)
Average Citations per Product	25.94 (Scopus)
Hirsch (H) index	24 (Scopus)

*Using impact factor of the year in which papers were published

Part XI- Selected Publications

List of the publications selected for the evaluation.

N	Publication (<i>title, authors, reference data</i>)	Impact Factor (<i>InCites; 2016</i>)	Impact Factor (<i>InCites; publication year</i>)	Total citations (<i>Scopus</i>)	Average Citations per Product (<i>Scopus</i>)
1	Type 2 deiodinase polymorphism (thr92ala) predicts l-thyroxine dose to achieve target TSH levels in thyroidectomized patients. Torlontano M*, Durante C* , Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V (<i>*Equal contribution</i>).	5,455	5,493	42	4,3

	<i>J Clin Endocrinol Metab.</i> 2008 Mar;93(3):910-913. doi: 10.1210/jc.2007-1067.				
2	Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E. <i>Endocr Relat Cancer.</i> 2009 Jun;16(2):585-97. doi: 10.1677/ERC-08-0301.	5,267	5,236	72	8,4
3	Identification and Optimal Postsurgical Follow-Up of Patients with Very Low-Risk Papillary Thyroid Microcarcinomas. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S; on behalf of the Papillary Thyroid Cancer Study Group. <i>J Clin Endocrinol Metab.</i> 2010 Nov;95(11):4882-8. doi: 10.1210/jc.2010-0762.	5,455	6,202	49	6,8
4	BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. <i>Eur J Endocrinol.</i> 2011	4,101	3,482	16	2,5

	Sep;165(3):455-63. doi: 10.1530/EJE-11-0283.				
5	Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S; on behalf of the PTC Study Group. <i>J Clin Endocrinol Metab.</i> 2012 Aug;97(8):2748-53. doi: 10.1210/jc.2012-1123.	5,455	5,967	52	9,6
6	Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S; on behalf of the PTC Study Group. <i>J Clin Endocrinol Metab.</i> 2013 Feb;98(2):636-42. doi: 10.1210/jc.2012-3401.	5,455	6,430	77	15,7
7	Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F,	5,515	3,843	27	7,7

	Toteda M, Redler A, Ronga G, Filetti S, Monzani F. <i>Thyroid</i> . 2014 Jul;24(7):1139-45. doi: 10.1089/thy.2013.0698.				
8	The natural history of benign thyroid nodules. Durante C , Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S. <i>JAMA</i> . 2015 Mar 3;313(9):926-35. doi: 10.1001/jama.2015.0956.	44,405	35,289	71	25,4
9	Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, Durante C . <i>Endocrine</i> . 2016 Jul;53(1):145-56. doi: 10.1007/s12020-015-0739-y.	3,131	3,279	4	2,7
10	Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C . <i>J Clin Endocrinol Metab</i> . 2016 Aug;101(8):3036-44. doi: 10.1210/jc.2016-1440.	5,455	5,531	3	2,1
11	Thyroid cancer. Cabanillas ME, McFadden DG, Durante C . <i>Lancet</i> . 2016 Dec 3;388(10061):2783-2795. doi: 10.1016/S0140-6736(16)30172-6.	47,831	44,002	28	25,9

12	Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume. Grani G, Bruno R, Lucisano G, Costante G, Meringolo D, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Cooper DS, Filetti S, Durante C. <i>Thyroid.</i> 2017 Nov;27(11):1378-1384. doi: 10.1089/thy.2017.0201	5,515	5,515	1	NA
		143,04	130,27	442	111,1

Luogo e data

Roma, 14/02/2018

Firma

Coimo 